These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine. Geraud GE Eur Neurol; 1996; 36 Suppl 2():24-7. PubMed ID: 8791029 [TBL] [Abstract][Full Text] [Related]
6. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group. Zagami AS Neurology; 1997 Mar; 48(3 Suppl 3):S25-8. PubMed ID: 9071267 [TBL] [Abstract][Full Text] [Related]
8. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Visser WH; Klein KB; Cox RC; Jones D; Ferrari MD Neurology; 1996 Feb; 46(2):522-6. PubMed ID: 8614525 [TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness of 311C90 in the acute treatment of migraine. Ferrari MD Eur Neurol; 1996; 36 Suppl 2():4-7. PubMed ID: 8791025 [TBL] [Abstract][Full Text] [Related]
10. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Limmroth V; Kazarawa Z; Fritsche G; Diener HC Lancet; 1999 Jan; 353(9150):378. PubMed ID: 9950449 [No Abstract] [Full Text] [Related]
11. Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura? Dowson A Eur Neurol; 1996; 36 Suppl 2():28-31. PubMed ID: 8791030 [TBL] [Abstract][Full Text] [Related]
12. Clinical safety of 311C90: aggregated data from patients and volunteers to date. Earl NL Eur Neurol; 1996; 36 Suppl 2():8-12. PubMed ID: 8791026 [TBL] [Abstract][Full Text] [Related]